[1] |
ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen.
Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
|
[2] |
CHENG Kuan.
New progress in research and application of fenneridone
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 450-456.
|
[3] |
LIU Weiyi, SUN Jianguo, CAO Weiling, WANG Guangji, WANG Hong.
Advances in farnesoid X receptor antagonists and their pharmacological activities
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 764-774.
|
[4] |
CHEN Yu,YIN Weiyong,CHEN Yanyan,ZHU Zhenguo,ZHENG Rongyuan,ZHENG Liupu.
Effects of adenosine A2A receptor antagonist on lipopolysaccharide induced inflammatory BV-2 microglial cells' morphology and function
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1376-1384.
|
[5] |
LUO Shengyong, JIA Dewu, LI Xiaoyi, DAI Xiangrong.
Study on the protective mechanism of anti-platelet thrombolysin against cerebral ischemia reperfusion injury in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1109-1115.
|
[6] |
WANG Pei-yu, YU Rong, LIN Jin-ju, XIAO Shi-quan, JIN Cong-cong, ZHU Ru-ru.
Comparison of GnRH antagonist and GnRH agonist used in IVF-ET in patients with PCOS
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 795-800.
|
[7] |
ZHANG Yin-zhuang, CHEN Bi-lian.
Research progress on the platelet P2Y12 receptor antagonists
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 824-830.
|
[8] |
ZHAO Tian, GU Liang, DU Jian-zong, QIN Guang-yue.
Analysis of therapeutic effect of montelukast in elderly stable patients with moderate on severe chronic obstructive pulmonary disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 66-70.
|
[9] |
HU Ai-hong, LI Xiao-ming, MA Huan-jie.
A Meta-analysis of histamine-receptor antagonists use and risk of pneumonia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 536-542.
|
[10] |
CHEN Wang, YU Jing, QU Qiang, ZHANG Wei, LI Zhi, WU Lan-xiang, WEN Chun-jie, ZHOU Hong-hao.
Construction of human CYP2C19 gene polymorphism eukaryotic expression vector and establishment of stably transfected HepG2 cell line expressing human CYP2C19
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 263-268.
|
[11] |
LIN Xi, YANG Fang, WU Bin, ZHANG Xiaoyan, LIN Chun.
Ramosetron decrease visceral pain hypersensitivity in young rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1102-1107.
|
[12] |
CHEN Ai-dong, LI Juan, XIE Hai-tang.
Recent research progress in cardiovascular effects of endothelin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(8): 937-944.
|
[13] |
LI Xiao-qian, KE Yong-sheng.
Progression of no-reflow prevention and treatment in percutaneous coronary intervention
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 595-600.
|
[14] |
WU Yan.
Clinical investigation of ACE inhibitor combined with calcium antagonist on the patients with mild to moderate essential hypertension and it's effect on the serum uric acid level
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 317-321.
|
[15] |
WANG Wei, WANG Yu, WANG Ruo-ning, XU Su-ying, DING Yang, ZHOU Jian-ping.
Study on effects of novel cationic polymer nonviral vector-mediated wild-type p53 gene transfection in vitro
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1227-1233.
|